Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05247866 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
A Phase 4 study of Eosinophilic Esophagitis, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05247866 is a Phase 4 study of Eosinophilic Esophagitis that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 21 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05247866, a Phase 4 study of Eosinophilic Esophagitis, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of medications including proton pump inhibitors, topical steroids or biologics. Food elimination creates a decrease quality of life in many children. The goal of the study is to examine a T2 inhibitor (dupilumab) can allow successful reintroduction of allergic EoE foods into the diet. This is a single site study, enrolling subjects 6 to 25 years of age.
Conditions Studied
Interventions
- DRUG Dupilumab
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (EoE) food introduction-1st
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (E0E) food introduction-2nd
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (EoE) Food introduction-3rd dose
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2025-01-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05247866
The ClinicalTrials.gov registry entry for NCT05247866 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 4 interventions - of which Dupilumab is the first listed.
NCT05247866 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05247866 about?
NCT05247866 is a clinical study titled "Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis". Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of medications including proton pump inhibitors, topical steroids or biologics. Food elimination creates a d...
What is the current status of trial NCT05247866?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2022-06-16. Estimated completion is 2025-01-21.
What conditions does trial NCT05247866 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05247866?
The interventions under investigation include: Dupilumab (DRUG), Eosinophilic Esophagitis (EoE) food introduction-1st (DIETARY_SUPPLEMENT), Eosinophilic Esophagitis (E0E) food introduction-2nd (DIETARY_SUPPLEMENT), Eosinophilic Esophagitis (EoE) Food introduction-3rd dose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05247866?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05247866 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
ACTIVE NOT RECRUITING · Phase 4
-
Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
COMPLETED · Phase 4
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
A Registry for the Food Allergy Community
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.